Evaluation of the Safety and Immunogenicity of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With Melanoma (Mel59)
Latest Information Update: 18 Sep 2021
At a glance
- Drugs PBCAR3 phosphopeptide vaccine (Primary) ; PIRS2 phosphopeptide vaccine (Primary) ; 2-MpP; Montanide ISA-51; Poly ICLC; Tetanus vaccine
- Indications Malignant melanoma; Tetanus
- Focus Adverse reactions; Therapeutic Use
- 12 Aug 2016 Biomarkers information updated
- 13 May 2013 New trial record
- 01 May 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.